source
- Novartis' experimental heart drug pelacarsen fails pivotal Phase 3 trialNovartis announced that its experimental cardiovascular therapy, pelacarsen, did not meet its primary endpoints in the Phase 3 HORIZON trial. The study compared the drug to placebo and found no red…
- Ionis secures FDA approval for zilganersen, a first treatment for Alexander diseaseIonis Pharmaceuticals announced that the U.S. Food and Drug Administration has approved its antisense drug zilganersen for the treatment of Alexander disease, an ultra‑rare neurodegenerative disord…